サイトカインの基礎と臨床IL-2の臨床応用

IL-2の抗腫瘍効果をみるため, 4名の担癌患者にrecombinant (r) IL-2を3.3~10×105 U/日, 5~20日間点滴静注したが効果は認められなかった.ついで8名の従来の治療が無効な担癌患者に対しrIL-2のadoptive immunotherapyを行ったところ,多発性骨髄腫2例において,末梢血リンパ球数の増加, Leu 7, OKM 1, OKT 10陽性細胞の増加, NK, LAK活性の上昇がみられ,血中M蛋白濃度の25~50%の減少がみられた.皮膚悪性リンパ腫の患者では皮膚病変の改善が,赤白血病では白血病に至るstageを遅延させている所見がみられた....

Full description

Saved in:
Bibliographic Details
Published in日本臨床免疫学会会誌 Vol. 9; no. 5; pp. 345 - 349
Main Author 戸川, 敦
Format Journal Article
LanguageJapanese
Published 日本臨床免疫学会 1986
Online AccessGet full text
ISSN0911-4300
1349-7413
DOI10.2177/jsci.9.345

Cover

Abstract IL-2の抗腫瘍効果をみるため, 4名の担癌患者にrecombinant (r) IL-2を3.3~10×105 U/日, 5~20日間点滴静注したが効果は認められなかった.ついで8名の従来の治療が無効な担癌患者に対しrIL-2のadoptive immunotherapyを行ったところ,多発性骨髄腫2例において,末梢血リンパ球数の増加, Leu 7, OKM 1, OKT 10陽性細胞の増加, NK, LAK活性の上昇がみられ,血中M蛋白濃度の25~50%の減少がみられた.皮膚悪性リンパ腫の患者では皮膚病変の改善が,赤白血病では白血病に至るstageを遅延させている所見がみられた.
AbstractList IL-2の抗腫瘍効果をみるため, 4名の担癌患者にrecombinant (r) IL-2を3.3~10×105 U/日, 5~20日間点滴静注したが効果は認められなかった.ついで8名の従来の治療が無効な担癌患者に対しrIL-2のadoptive immunotherapyを行ったところ,多発性骨髄腫2例において,末梢血リンパ球数の増加, Leu 7, OKM 1, OKT 10陽性細胞の増加, NK, LAK活性の上昇がみられ,血中M蛋白濃度の25~50%の減少がみられた.皮膚悪性リンパ腫の患者では皮膚病変の改善が,赤白血病では白血病に至るstageを遅延させている所見がみられた.
Author 戸川, 敦
Author_xml – sequence: 1
  fullname: 戸川, 敦
  organization: 国立病院医療センター内科
BookMark eNo9Tz1Lw0AYPqSCaXXxf1x87zs3avGjEHDR-bikd5pQqyRdHBsHxcHJUXDpEBBcxKWLPyaE-jOsrTg8PF_wwNNFnfH12CG0SyCkRKm9vEyzUIeMiw0UEMY1VpywDgpAE4I5A9hC3bLMAZhgigdINdVnU82au4emeluJj2b63r7OF7OnZlp_39ft_HEQY7pM16b9elk819to09tR6Xb-uIfOjw7P-ic4Pj0e9PdjnBPNAFMqIwlSacf0MJFUy0RRDxySSA2Vc5EmUiU88eCptgxsZKUXiaAA2nMlWA8drHfzcmIvnLkpsitb3BpbTLJ05MzvYaJVZLQRKyyv_5fppS1MbtkP0pVj-w
ContentType Journal Article
Copyright 日本臨床免疫学会
Copyright_xml – notice: 日本臨床免疫学会
DOI 10.2177/jsci.9.345
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1349-7413
EndPage 349
ExternalDocumentID article_jsci1978_9_5_9_5_345_article_char_ja
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
CS3
EBS
EJD
F5P
JSF
KQ8
OK1
RJT
ID FETCH-LOGICAL-j1930-226860679e39db6296b72f040b87d7ee89167b4bf0f29a30a8a6f5b52009f4753
ISSN 0911-4300
IngestDate Wed Sep 03 06:28:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue 5
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j1930-226860679e39db6296b72f040b87d7ee89167b4bf0f29a30a8a6f5b52009f4753
OpenAccessLink https://www.jstage.jst.go.jp/article/jsci1978/9/5/9_5_345/_article/-char/ja
PageCount 5
ParticipantIDs jstage_primary_article_jsci1978_9_5_9_5_345_article_char_ja
PublicationCentury 1900
PublicationDate 19860000
PublicationDateYYYYMMDD 1986-01-01
PublicationDate_xml – year: 1986
  text: 19860000
PublicationDecade 1980
PublicationTitle 日本臨床免疫学会会誌
PublicationTitleAlternate 日臨免誌
PublicationYear 1986
Publisher 日本臨床免疫学会
Publisher_xml – name: 日本臨床免疫学会
References 5) Ettinghausen, S. E., Rosenberg, S. A.: Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res., 46: 2784-2792, 1986.
2) Lotze, M. T., Robb, R. J., Sharrow, S. O., Frana, L. W., Rosenberg, S. A.: Systemic administration of interleukin-2 in humans. J. Biol. Response Mod., 3: 475-482, 1984.
3) Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, A. Y., Custer, M. C., Rosenberg, S. A.: in vivo administration of purified human interleukin 2 II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol., 135: 2865-2875, 1985.
1) Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S. L., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., Reichert, C. M.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl. J. Med., 313: 1485-1492, 1985.
4) Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M., Schwarz, S. L.: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Med., 61: 1169-1188, 1985.
References_xml – reference: 2) Lotze, M. T., Robb, R. J., Sharrow, S. O., Frana, L. W., Rosenberg, S. A.: Systemic administration of interleukin-2 in humans. J. Biol. Response Mod., 3: 475-482, 1984.
– reference: 1) Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S. L., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., Reichert, C. M.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl. J. Med., 313: 1485-1492, 1985.
– reference: 4) Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M., Schwarz, S. L.: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Med., 61: 1169-1188, 1985.
– reference: 3) Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, A. Y., Custer, M. C., Rosenberg, S. A.: in vivo administration of purified human interleukin 2 II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol., 135: 2865-2875, 1985.
– reference: 5) Ettinghausen, S. E., Rosenberg, S. A.: Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res., 46: 2784-2792, 1986.
SSID ssj0035374
Score 1.2423548
Snippet IL-2の抗腫瘍効果をみるため, 4名の担癌患者にrecombinant (r) IL-2を3.3~10×105 U/日, 5~20日間点滴静注したが効果は認められなかった.ついで8名の従来の治療が無効な担癌患者に対しrIL-2のadoptive...
SourceID jstage
SourceType Publisher
StartPage 345
Title サイトカインの基礎と臨床IL-2の臨床応用
URI https://www.jstage.jst.go.jp/article/jsci1978/9/5/9_5_345/_article/-char/ja
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 日本臨床免疫学会会誌, 1986/10/31, Vol.9(5), pp.345-349
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV29i9RAFB_OE8FG_OT85AqnzJpkvrGa7GY5PxCEO7guJJtMscWeyF6h3a2FYmFlKdhcsSDYiM01_jFhOf8M38wke3G5wlMhCS8z895k8h6Z35uPF4TuG4uJeUGCamRMQFUZBkVUsgBcZlqWSqoqdwtkn_GtHfp4l-2undvorFranxa90etT95X8jVYhDfRqd8meQbNLoZAANOgXrqBhuP6RjnFKsIxxwhpCU0fAIduUZDUrIY6IsE5xyrAa4kTjVNgCMm2zgF1iKRzBbAGpHz0N4g7narYjhlj1rSxFIasLe3HKsYLyzBF9rPunS5BwDJwE7h6dYT3AmuOU4qSPle4QEmvgWo7xWsHQ6sTLAwEDazyuOhDCTwY3ItUExbaG-L-eqzvgGYG3TEI_C1T5zz2hKgBMRbr9geqYPet824mPe9nABOIjra72QLGfAx8Dfump3pLlt4jejb1ktlAEXnymMuZOKJ61mXbTXTYG5H8-FiKyi1WfPF_OjxFGfHzxtk0-8K6t_MFJ1QCqxuBitMsTHWLavowuNa7OpvZVXUFr1eQquuB_fvrqGhL17Hs9O6zfvKtnXxzxrT74uvh8dHz4oT6Y_3w7Xxy9t1YHqf5m8ePT8cf5dbQzTLf7W0HzG49gDN5BGADAl9yOV1ZElQWPFS9EbKDzKKQoRVVJ8FBEQQsTmljlJMxlzg0rXDwwQ8GdvoHWJ3uTagNtQmfMJaE8NyMB0DLPTQk8ZUSZAlwajm6ih77F2QsfqyU7y7u-9U_ct9FFa8F-eO4OWp--3K_uAmCdFvec7n4BO6t7cA
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%82%B5%E3%82%A4%E3%83%88%E3%82%AB%E3%82%A4%E3%83%B3%E3%81%AE%E5%9F%BA%E7%A4%8E%E3%81%A8%E8%87%A8%E5%BA%8AIL-2%E3%81%AE%E8%87%A8%E5%BA%8A%E5%BF%9C%E7%94%A8&rft.jtitle=%E6%97%A5%E6%9C%AC%E8%87%A8%E5%BA%8A%E5%85%8D%E7%96%AB%E5%AD%A6%E4%BC%9A%E4%BC%9A%E8%AA%8C&rft.au=%E6%88%B8%E5%B7%9D%2C+%E6%95%A6&rft.date=1986&rft.pub=%E6%97%A5%E6%9C%AC%E8%87%A8%E5%BA%8A%E5%85%8D%E7%96%AB%E5%AD%A6%E4%BC%9A&rft.issn=0911-4300&rft.eissn=1349-7413&rft.volume=9&rft.issue=5&rft.spage=345&rft.epage=349&rft_id=info:doi/10.2177%2Fjsci.9.345&rft.externalDocID=article_jsci1978_9_5_9_5_345_article_char_ja
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0911-4300&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0911-4300&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0911-4300&client=summon